Peptide YY (human) (trifluoroacetate salt)
(Synonyms: Peptide Tyrosine Tyrosine) 目录号 : GC44598Peptide YY (human) (trifluoroacetate salt)是由肠道L细胞分泌的一种肽类激素。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Peptide YY (human) (trifluoroacetate salt) is a peptide hormone secreted by intestinal L cells [1]. Peptide YY binds to Y2 receptors on the hypothalamus and vagus nerve, inhibiting the release of neuropeptide Y, thereby reducing appetite, delaying gastric emptying, and decreasing intestinal motility [2-3]. Peptide YY is primarily used in the research of diseases such as obesity, diabetes, and metabolic syndrome [4].
In diet-induced obesity mice model, Continuous administration of Peptide YY (1mg/kg; sc; 7d) can significantly inhibit food intake and induce weight loss, with an average weight loss of approximately 8.3%, showing a stable and sustainable anorectic effect [5]. In C57BLKS/J db/db mice, the combined use of Peptide YY (1mg/kg; sc; 14d) and GLP-1 can significantly increase the glucose infusion rate, enhance the systemic glucose disposal rate, and inhibit hepatic glucose production, thereby improving insulin sensitivity [6].
References:
[1]. Batterham R L, Bloom S R. The gut hormone peptide YY regulates appetite[J]. Annals of the New York Academy of Sciences, 2003, 994(1): 162-168.
[2]. Peptide YY binds to Y2 receptors on the hypothalamus and vagus nerve, inhibiting the release of neuropeptide Y, thereby reducing appetite, delaying gastric emptying, and decreasing intestinal motility
[3]. Wu Y, He H, Cheng Z, et al. The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis[J]. Current Protein and Peptide Science, 2019, 20(7): 750-758.
[4]. Lafferty R A, Flatt P R, Irwin N. Emerging therapeutic potential for peptide YY for obesity-diabetes[J]. Peptides, 2018, 100: 269-274.
[5]. Nishizawa N, Niida A, Adachi Y, et al. Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice[J]. Bioorganic & Medicinal Chemistry Letters, 2017, 27(16): 3829-3832.
[6]. Boland B B, Laker R C, O'Brien S, et al. Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries[J]. Molecular metabolism, 2022, 55: 101392.
Peptide YY (human) (trifluoroacetate salt)是由肠道L细胞分泌的一种肽类激素 [1]。Peptide YY与下丘脑和迷走神经上的Y2受体结合，抑制神经肽Y的释放，从而降低食欲，延缓胃排空，降低肠道蠕动 [2-3]。Peptide YY主要用于肥胖、糖尿病和代谢综合征等疾病的研究 [4]。
在饮食诱导的肥胖小鼠模型中，持续给予Peptide YY（1mg/kg；sc；7d）可显著抑制摄食并诱导体重减轻，平均体重减轻约8.3%，显示出稳定且可持续的减食作用 [5]。在C57BLKS/J db/db小鼠中，Peptide YY（1mg/kg；sc；14d）与GLP-1联合使用可显著增加葡萄糖输注速率，增强全身葡萄糖处理率，并抑制肝脏葡萄糖生成，从而改善胰岛素敏感性 [6]。
| Animal experiment [1]: | |
Animal models | Diet-induced obesity mice model |
Preparation Method | In this study, the in vivo efficacy and pharmacokinetic characteristics of Peptide YY and its derivative peptides were evaluated in C57BL/6J mice with diet-induced obesity by continuous subcutaneous administration of Peptide YY (1mg/kg/day for 7 days). |
Dosage form | 1mg/kg; sc; 7d |
Applications | Continuous administration of Peptide YY can significantly inhibit food intake and induce weight loss, with an average weight loss of approximately 8.3%, showing a stable and sustainable anorectic effect. |
References: | |
| Cas No. | SDF | ||
| 别名 | Peptide Tyrosine Tyrosine | ||
| 化学名 | L-tyrosyl-L-prolyl-L-isoleucyl-L-lysyl-L-prolyl-L-α-glutamyl-L-alanyl-L-prolylglycyl-L-α-glutamyl-L-α-aspartyl-L-alanyl-L-seryl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-leucyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-alanyl-L-seryl-L-leucyl-L-arginyl-L-histidyl-L-tyrosyl-L-leucyl-L-asparaginyl-L-leucyl-L-valyl-L-threonyl-L-arginyl-L-glutaminyl-L-arginyl-L-tyrosinamide, trifluoroacetate salt | ||
| 分子式 | C194H295N55O57•XCF3COOH | 分子量 | 4309.8 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 232 μL | 1.1601 mL | 2.3203 mL |
| 5 mM | 46.4 μL | 232 μL | 464.1 μL |
| 10 mM | 23.2 μL | 116 μL | 232 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet